BostonGene, a prominent provider of AI-based molecular and immune profiling solutions, has announced a master agreement with Johns Hopkins University School of Medicine (JHUSOM) to collaborate on multiple clinical research projects. This partnership enables BostonGene and JHUSOM to further explore and validate innovative precision medicine approaches.

Under this agreement, JHUSOM will collaborate with BostonGene on a molecular characterization study focused on patients' tumors, microenvironment, and immune systems, with an emphasis on predicting treatment responses. BostonGene's solution will facilitate in-depth analysis, interpretation, and visualization of extensive data collected from genomic, transcriptomic, proteomic, and imaging studies of cancer patients. The goal is to identify significant somatic alterations, assess protein expression, calculate tumor clonality and heterogeneity, determine the composition of tumor microenvironment cell types, evaluate hereditary predisposition, assess viral infections, examine pharmacogenomics, and predict neoantigens for personalized vaccine development, among other molecular features. BostonGene will conduct comprehensive bioinformatics analyses to validate hypothesis-driven research and identify targetable molecular alterations.

Nathan Fowler, MD, Chief Medical Officer at BostonGene, expressed the company's honor in collaborating with JHUSOM to provide AI-based molecular and immune profiling techniques that comprehensively analyze the tumor, microenvironment, and immune system. The goal is to identify treatable targets that can personalize therapy for patients. This collaboration aligns with BostonGene's mission to assist healthcare professionals in finding the most effective personalized treatment options for their patients.